The new coronavirus pandemic is an international emergency that is causing severe medical burden.
Covid-19 is the new corona virus-induced disease and SARS-CoV-2 is the RNA coronavirus, which is also called Covid-19 virus by World Health Organization (WHO). The Covid-19 virus is highly contagious and causes high morbidity – with severe cases requiring hospitalisation and ventilatory support which can overwhelm national health systems – and significant mortality and for which there is no demonstrated effective vaccine or treatment.
Hence, many repurposed drugs are being tested for their usefulness in COVID-19.
OXON is working with an international team of academics, and clinicians who treat COVID-19 patients, to help provide reliable evidence to make decisions about pharmacological interventions in hospitalized COVID-19 patients.
OVERVIEW OF THE PROGRAMME